Mar 24, 2020
Dr. Hartmut Ehrlich, CEO, Abivax gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results. Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases.
@abivax #abivax #inflammation #IBD #rheum